Back to results
US 12,589,171 B2Granted
177-Lu labeled peptide for site-specific uPAR-targeting
AssigneeTRT Innovations APS
InventorsAndreas Kjaer, Morten Persson, Michael Ploug
Life of this patent
Estimating the term…
Abstract
There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
Claims9
A 177-Lu labelled uPAR binding peptide conjugate, wherein the peptide is coupled to 177-Lu by a chelating agent, and wherein the uPAR binding peptide comprises a ([beta]-cyclohexyl-L-alanine)-(Phe)-X1—X2—X3—X4—X5 residue, wherein
- X1 represents Ser or D-Ser;
- X2 represents D-Arg, Arg, Gln, D-Tyr, or Tyr;
- X3 represents Tyr, Leu, [beta]-cyclohexyl-L-alanine, or N-(2,3-dimethoxybenzyl)glycine;
- X4 represents Leu or D-Phe;
- and
- X5 represents Trp, [beta]-2-naphthyl-L-alanine, N-(3-indolylethyl)glycine, N-benzylglycine, N-(methylnaphthalyl)glycine, or N-(2,3-dimethoxybenzyl)glycine.
3 more elements
Dependencies are inferred from the claim text.